MedTrace Logo

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2361

Last updated 2016-12-20

No results posted yet for this study

Summary

Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Dapsone 5.0% Gel (SEEGPharm)

Topical Gel

OTHER

Placebo

Topical Gel

DRUG

Dapsone 5.0% Gel (Allergan)

Topical Gel

Sponsors & Collaborators

  • Seegpharm S.A.

    lead INDUSTRY

Principal Investigators

  • Karen Lewis, MS · Catawba Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-11-30
Completion
2016-12-31

Countries

  • United States
  • Belize

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865005 on ClinicalTrials.gov